Activation of Matrix Metalloproteinases
REACTOME PATHWAYThe Activation of Matrix Metalloproteinases pathway (Reactome ID: R-HSA-1592389) involves 11 genes and is affected by 12 compounds in the BiohacksAI evidence corpus. Compound-pathway associations are derived from target overlap: a compound is linked to this pathway if it targets ≥2 genes within the pathway.
Genes in this Pathway
Compounds Affecting Activation of Matrix Metalloproteinases
| # | Compound | Targets Hit | Studies |
|---|---|---|---|
| 1 | Bortezomib | — | 300 |
| 2 | Sulfaguanidine | — | 255 |
| 3 | Gabexate | — | 300 |
| 4 | Resveratrol | — | 298 |
| 5 | Astemizole Antihistamine drug now withdrawn from | — | 280 |
| 6 | Leflunomide | — | 297 |
| 7 | Propafenone | — | 14 |
| 8 | Thioridazine | — | 35 |
| 9 | Ursolic Acid | — | 300 |
| 10 | Diminazene | — | 300 |
| 11 | silver sulfadiazine | — | 299 |
| 12 | Doxycycline | — | 999 |
About the Activation of Matrix Metalloproteinases Pathway
The Activation of Matrix Metalloproteinases pathway is catalogued in Reactome (ID: R-HSA-1592389) and involves 11 genes. In the BiohacksAI corpus, 12 compounds have documented interactions with at least 2 genes in this pathway, establishing mechanistic relevance. Key pathway genes include CMA1, CTRB1, CTSG, ELANE, FURIN.